~~<i id='5E1D409873'><strike id='5E1D409873'><tt id='5E1D409873'><pre id='5E1D409873'></pre></tt></strike></i>~~

Home» comprehensive» knowledge

knowledge

author：hotspot 2025-09-30 04:56:51 Page View：9376

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How Medicaid coverage policies for immigrants impact new moms
Next article： Supreme Court strikes down use of affirmative action

explore

The cancer drug shortage isn’t new — and neither are the solutions

PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

Doctors find melanoma drugs effective against rare brain cancer

Micrographofpapillarycraniopharyngeoma,inthebrain.Sarahkayb/WikimediaCommonsBygoingdowntothemolecula

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

CMSAdministratorChiquitaBrooks-LaSureChipSomodevilla/GettyImagesWASHINGTON— EliLilly’slatestanti-amy

$1 billion proposal to grow Boston, Massachusetts biotech

AscientistworkingatSQZBiotechnologiesinWatertown,Mass.DavidLRyan/GlobeStaffNextstop:BeaconHill.Gover

WSS

knowledge

knowledge

Wikipedia

explore

$1 billion proposal to grow Boston, Massachusetts biotech